Clinical, immunological, and pathological consequences of Fas-deficient conditions
- 1 September 1996
- journal article
- case report
- Published by Elsevier in The Lancet
- Vol. 348 (9029) , 719-723
- https://doi.org/10.1016/s0140-6736(96)02293-3
Abstract
No abstract availableKeywords
This publication has 16 references indexed in Scilit:
- Mutations in Fas Associated with Human Lymphoproliferative Syndrome and AutoimmunityScience, 1995
- Dominant interfering fas gene mutations impair apoptosis in a human autoimmune lymphoproliferative syndromeCell, 1995
- RIP: A novel protein containing a death domain that interacts with Fas/APO-1 (CD95) in yeast and causes cell deathCell, 1995
- FADD, a novel death domain-containing protein, interacts with the death domain of fas and initiates apoptosisCell, 1995
- Cell-autonomous Fas (CD95)/Fas-ligand interaction mediates activation-induced apoptosis in T-cell hybridomasNature, 1995
- Autocrine T-cell suicide mediated by APO-1/(Fas/CD95)Nature, 1995
- Fas ligand mediates activation-induced cell death in human T lymphocytes.The Journal of Experimental Medicine, 1995
- The fas antigen is involved in peripheral but not thymic deletion of T lymphocytes in T cell receptor transgenic miceImmunity, 1994
- Linkage of Bardet–Biedl syndrome to chromosome 16q and evidence for non–allelic genetic heterogeneityNature Genetics, 1993
- A novel lymphoproliferative/autoimmune syndrome resembling murine lpr/gld disease.Journal of Clinical Investigation, 1992